Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
27 08 2022
27 08 2022
Historique:
received:
25
04
2022
accepted:
15
08
2022
revised:
11
08
2022
entrez:
27
8
2022
pubmed:
28
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
In addition to an inflammatory reaction, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected patients present lymphopenia, which we recently reported as being related to abnormal programmed cell death. As an efficient humoral response requires CD4 T-cell help, we hypothesized that the propensity of CD4 T cells to die may impact the quantity and quality of the humoral response in acutely infected individuals. In addition to specific immunoglobulins (Ig)A, IgM, and IgG against SARS-CoV-2 nucleocapsid (N), membrane (M), and spike (S1) proteins, we assessed the quality of IgG response by measuring the avidity index. Because the S protein represents the main target for neutralization and antibody-dependent cellular cytotoxicity responses, we also analyzed anti-S-specific IgG using S-transfected cells (S-Flow). Our results demonstrated that most COVID-19 patients have a predominant IgA anti-N humoral response during the early phase of infection. This specific humoral response preceded the anti-S1 in time and magnitude. The avidity index of anti-S1 IgG was low in acutely infected individuals compared to convalescent patients. We showed that the percentage of apoptotic CD4 T cells is inversely correlated with the levels of specific IgG antibodies. These lower levels were also correlated positively with plasma levels of CXCL10, a marker of disease severity, and soluble Fas ligand that contributes to T-cell death. Finally, we found lower S-Flow responses in patients with higher CD4 T-cell apoptosis. Altogether, these results demonstrate that individuals with high levels of CD4 T-cell apoptosis and CXCL10 have a poor ability to build an efficient anti-S response. Consequently, preventing CD4 T-cell death might be a strategy for improving humoral response during the acute phase, thereby reducing COVID-19 pathogenicity.
Identifiants
pubmed: 36030261
doi: 10.1038/s41419-022-05190-0
pii: 10.1038/s41419-022-05190-0
pmc: PMC9419645
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
741Informations de copyright
© 2022. The Author(s).
Références
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
J Immunol. 1999 Mar 15;162(6):3549-58
pubmed: 10092813
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Lancet. 1988 Nov 12;2(8620):1104-7
pubmed: 2903324
Immunol Rev. 1997 Apr;156:53-66
pubmed: 9176699
J Exp Med. 1993 Jun 1;177(6):1809-14
pubmed: 8496693
Clin Vaccine Immunol. 2015 Dec 09;23(3):243-5
pubmed: 26656116
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
J Immunol. 2014 Dec 1;193(11):5370-8
pubmed: 25411432
J Clin Virol. 2020 Dec;133:104655
pubmed: 33069846
Cell. 1993 Dec 17;75(6):1169-78
pubmed: 7505205
Cell. 2020 Dec 10;183(6):1496-1507.e16
pubmed: 33171099
Immunity. 1998 Nov;9(5):711-20
pubmed: 9846492
Nat Cell Biol. 2021 Dec;23(12):1314-1328
pubmed: 34876692
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
J Infect Dis. 2021 Sep 1;224(5):764-770
pubmed: 34086960
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444980
PLoS One. 2017 Jan 3;12(1):e0169100
pubmed: 28046003
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
FASEB J. 1994 Aug;8(11):832-40
pubmed: 8070632
J Immunol. 1999 Jul 15;163(2):583-9
pubmed: 10395644
J Immunol. 2007 Nov 1;179(9):6237-45
pubmed: 17947699
Cell Death Differ. 2022 Jun;29(6):1107-1122
pubmed: 35581387
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33529167
Nature. 1995 Feb 2;373(6513):441-4
pubmed: 7530336
Am J Pathol. 2000 Jun;156(6):1951-9
pubmed: 10854218
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Med. 2021 Jul;27(7):1178-1186
pubmed: 33953384
Am J Respir Cell Mol Biol. 1998 Oct;19(4):537-42
pubmed: 9761749
Cell. 2020 Dec 10;183(6):1508-1519.e12
pubmed: 33207184
J Exp Med. 1992 Jun 1;175(6):1539-46
pubmed: 1588279
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Lancet. 2004 Feb 21;363(9409):617-9
pubmed: 14987888
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
J Clin Immunol. 2011 Jun;31(3):430-5
pubmed: 21318330
J Infect Dis. 1990 Jul;162(1):270-3
pubmed: 2192008
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
J Exp Med. 1989 Sep 1;170(3):1039-44
pubmed: 2788703
Nature. 2021 Jul;595(7865):114-119
pubmed: 33915568
FASEB J. 2004 Jan;18(1):191-3
pubmed: 14597565
J Biol Chem. 2008 Feb 8;283(6):3272-3280
pubmed: 18055455
PLoS Pathog. 2015 Dec 07;11(12):e1005287
pubmed: 26640894
Cell Death Differ. 2021 Sep;28(9):2765-2777
pubmed: 33879858
Nat Med. 1999 Apr;5(4):423-6
pubmed: 10202932
Immunol Rev. 2019 Mar;288(1):85-96
pubmed: 30874350
Cell Rep Med. 2021 Mar 16;2(3):100208
pubmed: 33564749
J Appl Lab Med. 2020 Sep 1;5(5):908-920
pubmed: 32428207
Nat Immunol. 2021 Apr;22(4):404-411
pubmed: 33723418
Microorganisms. 2020 Nov 28;8(12):
pubmed: 33260775
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
Nat Biomed Eng. 2020 Dec;4(12):1188-1196
pubmed: 33122853
Heliyon. 2021 Apr;7(4):e06836
pubmed: 33898857
Sci Transl Med. 2015 Jul 29;7(298):298ra120
pubmed: 26223303
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Nat Microbiol. 2021 Jan;6(1):51-58
pubmed: 33199863
Clin Diagn Lab Immunol. 1999 Sep;6(5):725-8
pubmed: 10473525
Sci Transl Med. 2020 Sep 2;12(559):
pubmed: 32817357
J Exp Med. 1987 Oct 1;166(4):1084-97
pubmed: 2443596
Cell Death Differ. 2022 Aug;29(8):1486-1499
pubmed: 35066575
Immunol Rev. 2005 Aug;206:32-63
pubmed: 16048541
J Exp Med. 1996 Sep 1;184(3):963-9
pubmed: 9064356
Microbios. 1996;87(351):113-21
pubmed: 9032960
J Clin Invest. 2020 Dec 1;130(12):6477-6489
pubmed: 32833687
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 32958614
Emerg Infect Dis. 2020 Oct;26(10):2484-2487
pubmed: 32579877
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Front Immunol. 2017 Feb 20;8:135
pubmed: 28265271
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
J Infect Dis. 2020 Sep 14;222(8):1265-1269
pubmed: 32726417
J Immunol. 1997 Oct 15;159(8):3961-7
pubmed: 9378984